Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 38kWORD 18k
10 July 2020
 E-000658/2020
Answer given by Ms Kyriakides
on behalf of the European Commission
Question reference: E-000658/2020

The Commission is working with Member States and international partners including the World Health Organisation (WHO) on all fronts to tackle the COVID-19 pandemic . The first priority is to guarantee the health and safety of everyone: protecting people from the spread of the virus, supporting the health systems and health workers while maintaining the flow of goods(1), mitigating the effects on the economy(2) and helping people get back to their homes.

Decisions are guided by scientific evidence. A new advisory panel of specialists was created specifically on COVID-19, working with the European Centre for Disease Prevention and Control and the European Medicine Agency to guide the Commission.

The Commission is funding research on potential COVID-19 vaccine and treatments(3) including EUR 47.5 million through an emergency call for expressions of interest and up to EUR 45 million via the Innovative Medicines Initiative (IMI), which is expected to be matched with a similar investment by the industry(4).

Additionally, the Commission offered up to EUR 80 million of financial support to CureVac, a highly innovative vaccine developer, to scale up European development and production of a vaccine against the Coronavirus. The Commission hosted, in close cooperation with the WHO, a pledging marathon raising EUR 9.8 billion so far for vaccine development, treatments and diagnostics(5).

Together with many Member States, the Commission has launched joint procurement tenders for essential medical and protective equipment and has created the first ever rescEU stockpile(6).

The Commission has set up a COVID-19 website(7) to keep all citizens informed of the comprehensive response by the Commission.

(1)https://ec.europa.eu/commission/presscorner/detail/en/IP_20_468
(2)https://ec.europa.eu/commission/presscorner/detail/en/ip_20_459
(3)https://ec.europa.eu/info/live-work-travel-eu/health/coronavirus-response/research-and-innovation_en
(4)https://ec.europa.eu/info/research-and-innovation/research-area/health-research-and-innovation/coronavirus-research_en
(5)https://global-response.europa.eu/index_en
(6)https://ec.europa.eu/commission/presscorner/detail/en/ip_20_476
(7)https://ec.europa.eu/info/live-work-travel-eu/health/coronavirus-response_en
Last updated: 13 July 2020Legal notice - Privacy policy